Anti-Obesity Prescription Drugs Market was valued at USD 2.97 Bn. in 2024 and the total Global Anti-Obesity Prescription Drugs Market revenue is Expected to grow at a CAGR of 4.9% from 2025 to 2032 reaching nearly USD 4.35 Bn. by 2032. According to past study 650 Mn individuals in 1965 had corpulent body and recent study data shows the obesity has tripled in 2023, giving a number of 1.6 Bn individuals who are suffering from overweight problems. A corpulent individual is at a higher risk of developing chronic diseases like endometrial cancer, breast cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.To know about the Research Methodology :- Request Free Sample Report The drug which inhibit fat absorption, energy intake, enhance energy expenditure and stimulate fat mobilization are known as Anti-Obesity Drugs. The FDA has approved five different types of Anti-Obesity Prescription Drugs lorcaserin (Belviq), orlistat (Xenical), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and liraglutide (Saxenda).Global Anti-Obesity Prescription Drugs Market Drivers and RestrainsThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. According to, Disease Control & Prevention Centers show that 68.8% of the United State population is obese. The increasing incidence of the condition is followed by growing awareness of the same. Because of, the increasing awareness of anxiety that customers shift to anti-obesity drugs is rising at a prominent step. Obesity can be credited as an incurable chronic disease that increases the risk of cardiovascular diseases like diabetes, hypertension, and strokes. Sometimes, lifestyle intervention fails to impart potential results and a huge proportion of patients obvert their customary standards to enhance positive clinical outcome with the consumption of prescribed weight loss drugs. Advanced technique of skin patch delivery that permits for the administration of anti-obesity prescription drugs with low risk of side effects. Furthermore, the development of Nano Soy-Phytosome based thermo gels as the interesting formulations of anti-obesity is a key novelty in the market. Herbal supplements are the recent trend in the anti-obesity prescription drugs market. These trends are expected to boost opportunities for the growth of sellers in the global anti-obesity drugs market. The top Food and Drug Administration (FDA) approved anti-obesity drugs are Contrave, Belviq, Xenical, Saxenda and Qsymia. In United State, Xenical was the largest selling drug in the market until 2012, because of the character for unpleasant gastrointestinal side effects showed by Xenical. Though, recently approved Saxenda by Novo Nordisk Pharma is gaining large interest between obese individuals and is growing at a unanimous rate. Manufacturers in the Anti-Obesity Prescription Drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
Segment Analysis
Based on the Drug type the Anti-Obesity Prescription Drugs Market is segmented into Contrave, Belviq, Xenical, Saxenda and Qsymia. Saxenda segment dominated the market in 2024 and is expected to hold largest share during the forecast period. Saxenda, a GLP-1 receptor agonist, gained strong adoption due to its high efficacy in weight management, ability to improve metabolic health, and proven clinical outcomes compared to other drugs. Rising obesity prevalence, physician preference for GLP-1 therapies, and favorable reimbursement policies further boosted demand. Its dual benefits of weight reduction and diabetes risk management made it the most widely prescribed option. Based on the Application the Market is Segmented into Hospitals Pharmacies, Retail Pharmacies and E-commerce. Hospital Pharmacies dominated the market in 2024 and is expected to hold largest share during the forecast period. Hospitals serve as the primary channel for prescribing and dispensing anti-obesity and weight management drugs, as they are directly linked with physician consultations and patient monitoring. The strong trust factor, immediate availability of prescribed medications, and integration with treatment plans give hospital pharmacies an advantage over retail and e-commerce channels, making them the largest contributor to overall market revenue.Regional Insights
In terms of regional analysis North America is expected to emerge as a leading region in the global anti-obesity prescription drugs market during the forecast period. Because of the awareness of obesity among the population and the risks associated with the health situation have resulted in the anti-obesity prescription drugs market describing flourished growth in the region over the years. The Asia Pacific market for anti-obesity prescription drugs is anticipated to drive in the coming years, thanks to the rise in obese population. The European Medicines Agency (EMA), retreated the utilization of a series of anti-obesity drugs attributed to prohibited proportion of threat to benefit ratio, in 2000. Anti-obesity prescriptive drug like Rimonabant was available in more than 55 countries Afterward, in the year 2009 Rimonabant was withdrawn from the European anti-obesity prescription drugs market due to serious psychiatric side effects. In recent times, numerous development have been tested and examined, but only orlistat and sibutramine have been permitted for long-term use. The objective of the report is to present comprehensive analysis of Global Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Market dynamics, structure by analyzing the market segments, and project the Global Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.Anti-Obesity Prescription Drugs Market Scope: Inquire before buying
Anti-Obesity Prescription Drugs Market Report Coverage Details Base Year: 2024 Forecast Period: 2025-2032 Historical Data: 2019 to 2024 Market Size in 2024: USD 2.97 Bn. Forecast Period 2025 to 2032 CAGR: 4.9% Market Size in 2032: USD 4.35 Bn. Segments Covered: by Drug Type Contrave Belviq Xenical Saxenda Qsymia by Type Prescription Drugs OTC Drugs by Drug class Peripherally Acting Anti-obesity Drugs Centrally Acting Anti-obesity Drugs by Sales channel Direct Channel Distribution Channel by Application Hospitals Pharmacies Retail Pharmacies E-commerce Anti-Obesity Prescription Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Anti-Obesity Prescription Drugs Market, Key Players
1. F Hoffmann La Roche 2. Arena Pharmaceuticals 3. Orexigen Therapeutics 4. Phentermine and Topiramate 5. VIVUS, Inc 6. Liraglutide 7. Bupropion and Naltrexone 8. Orlistat 9. Novo Nordisk 10.Lorcaserin 11.GlaxoSmith Kline 12.Eisai Co, Ltd 13.Boehringer Ingelheim 14.Merck & Co 15.Pfizer 16.Rhythm Pharmaceuticals 17.Zafgan 18.Takeda Pharmaceuticals 19.Novo Nordisk 20.Bristol-Myers Squibb Co. 21.Shionogi USA Inc 22.Norgine byFrequently Asked Questions:
1.Which region has the largest share in Global Anti-Obesity Prescription Drugs Market? Ans: North America region held the highest share in 2024. 2.What is the growth rate of Global Anti-Obesity Prescription Drugs Market? Ans: The global market is growing at a CAGR of 4.9% during forecasting period 2025-2032. 3.What is scope of the Global Anti-Obesity Prescription Drugs market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4.Who are the key players in Global market? Ans: The important key players in the global market are – Phentermine and Topiramate, VIVUS, Inc, F Hoffmann La Roche, Liraglutide, Norgine bv, Bupropion and Naltrexone, Orlistat, Novo Nordisk, Lorcaserin, GlaxoSmith Kline, Eisai Co, Ltd, Boehringer Ingelheim, Merck & Co, Pfizer, Rhythm Pharmaceuticals, Zafgan, Takeda Pharmaceuticals, Novo Nordisk, Bristol-Myers Squibb Co., and Shionogi USA Inc. 5. What is the study period of this market? Ans: The Global Market is studied from 2024 to 2032.
1. Anti-Obesity Prescription Drugs Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global Anti-Obesity Prescription Drugs Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Landscape 2.3. Key Players Benchmarking 2.3.1. Company Name 2.3.2. Business Segment 2.3.3. End-user Segment 2.3.4. Revenue (2024) 2.3.5. Company Locations 2.4. Leading Anti-Obesity Prescription Drugs Market Companies, by market capitalization 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 3. Anti-Obesity Prescription Drugs Market: Dynamics 3.1. Anti-Obesity Prescription Drugs Market Trends by Region 3.1.1. North America Anti-Obesity Prescription Drugs Market Trends 3.1.2. Europe Anti-Obesity Prescription Drugs Market Trends 3.1.3. Asia Pacific Anti-Obesity Prescription Drugs Market Trends 3.1.4. Middle East and Africa Anti-Obesity Prescription Drugs Market Trends 3.1.5. South America Anti-Obesity Prescription Drugs Market Trends 3.2. Anti-Obesity Prescription Drugs Market Dynamics by Region 3.2.1. North America 3.2.1.1. North America Anti-Obesity Prescription Drugs Market Drivers 3.2.1.2. North America Anti-Obesity Prescription Drugs Market Restraints 3.2.1.3. North America Anti-Obesity Prescription Drugs Market Opportunities 3.2.1.4. North America Anti-Obesity Prescription Drugs Market Challenges 3.2.2. Europe 3.2.2.1. Europe Anti-Obesity Prescription Drugs Market Drivers 3.2.2.2. Europe Anti-Obesity Prescription Drugs Market Restraints 3.2.2.3. Europe Anti-Obesity Prescription Drugs Market Opportunities 3.2.2.4. Europe Anti-Obesity Prescription Drugs Market Challenges 3.2.3. Asia Pacific 3.2.3.1. Asia Pacific Anti-Obesity Prescription Drugs Market Drivers 3.2.3.2. Asia Pacific Anti-Obesity Prescription Drugs Market Restraints 3.2.3.3. Asia Pacific Anti-Obesity Prescription Drugs Market Opportunities 3.2.3.4. Asia Pacific Anti-Obesity Prescription Drugs Market Challenges 3.2.4. Middle East and Africa 3.2.4.1. Middle East and Africa Anti-Obesity Prescription Drugs Market Drivers 3.2.4.2. Middle East and Africa Anti-Obesity Prescription Drugs Market Restraints 3.2.4.3. Middle East and Africa Anti-Obesity Prescription Drugs Market Opportunities 3.2.4.4. Middle East and Africa Anti-Obesity Prescription Drugs Market Challenges 3.2.5. South America 3.2.5.1. South America Anti-Obesity Prescription Drugs Market Drivers 3.2.5.2. South America Anti-Obesity Prescription Drugs Market Restraints 3.2.5.3. South America Anti-Obesity Prescription Drugs Market Opportunities 3.2.5.4. South America Anti-Obesity Prescription Drugs Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Analysis 3.5. Technology Roadmap 3.6. Regulatory Landscape by Region 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Middle East and Africa 3.6.5. South America 3.7. Key Opinion Leader Analysis For Anti-Obesity Prescription Drugs Industry 3.8. Analysis of Government Schemes and Initiatives For Anti-Obesity Prescription Drugs Industry 3.9. Anti-Obesity Prescription Drugs Market Trade Analysis 3.10. The Global Pandemic Impact on Anti-Obesity Prescription Drugs Market 4. Anti-Obesity Prescription Drugs Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2024-2032 4.1. Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 4.1.1. Contrave 4.1.2. Belviq 4.1.3. Xenical 4.1.4. Saxenda 4.1.5. Qsymia 4.2. Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 4.2.1. Prescription Drugs 4.2.2. OTC Drugs 4.3. Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 4.3.1. Peripherally Acting Anti-Obesity Drugs 4.3.2. Centrally Acting Anti-obesity Drugs 4.4. Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 4.4.1. Direct Channel 4.4.2. Distribution Channel 4.5. Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 4.5.1. Hospitals Pharmacies 4.5.2. Retail Pharmacies 4.5.3. E-commerce 4.6. Anti-Obesity Prescription Drugs Market Size and Forecast, by Region (2024-2032) 4.6.1. North America 4.6.2. Europe 4.6.3. Asia Pacific 4.6.4. Middle East and Africa 4.6.5. South America 5. North America Anti-Obesity Prescription Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 5.1. North America Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 5.1.1. Contrave 5.1.2. Belviq 5.1.3. Xenical 5.1.4. Saxenda 5.1.5. Qsymia 5.2. North America Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 5.2.1. Prescription Drugs 5.2.2. OTC Drugs 5.3. North America Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 5.3.1. Peripherally Acting Anti-Obesity Drugs 5.3.2. Centrally Acting Anti-obesity Drugs 5.4. North America Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 5.4.1. Direct Channel 5.4.2. Distribution Channel 5.5. North America Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 5.5.1. Hospitals Pharmacies 5.5.2. Retail Pharmacies 5.5.3. E-commerce 5.6. North America Anti-Obesity Prescription Drugs Market Size and Forecast, by Country (2024-2032) 5.6.1. United States 5.6.1.1. United States Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 5.6.1.1.1. Contrave 5.6.1.1.2. Belviq 5.6.1.1.3. Xenical 5.6.1.1.4. Saxenda 5.6.1.1.5. Qsymia 5.6.1.2. United States Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 5.6.1.2.1. Prescription Drugs 5.6.1.2.2. OTC Drugs 5.6.1.3. United States Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 5.6.1.3.1. Peripherally Acting Anti-Obesity Drugs 5.6.1.3.2. Centrally Acting Anti-obesity Drugs 5.6.1.4. United States Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 5.6.1.4.1. Direct Channel 5.6.1.4.2. Distribution Channel 5.6.1.5. United States Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 5.6.1.5.1. Hospitals Pharmacies 5.6.1.5.2. Retail Pharmacies 5.6.1.5.3. E-commerce 5.6.2. Canada 5.6.2.1. Canada Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 5.6.2.1.1. Contrave 5.6.2.1.2. Belviq 5.6.2.1.3. Xenical 5.6.2.1.4. Saxenda 5.6.2.1.5. Qsymia 5.6.2.2. Canada Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 5.6.2.2.1. Prescription Drugs 5.6.2.2.2. OTC Drugs 5.6.2.3. Canada Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 5.6.2.3.1. Peripherally Acting Anti-Obesity Drugs 5.6.2.3.2. Centrally Acting Anti-obesity Drugs 5.6.2.4. Canada Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 5.6.2.4.1. Direct Channel 5.6.2.4.2. Distribution Channel 5.6.2.5. Canada Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 5.6.2.5.1. Hospitals Pharmacies 5.6.2.5.2. Retail Pharmacies 5.6.2.5.3. E-commerce 5.6.3. Mexico 5.6.3.1. Mexico Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 5.6.3.1.1. Contrave 5.6.3.1.2. Belviq 5.6.3.1.3. Xenical 5.6.3.1.4. Saxenda 5.6.3.1.5. Qsymia 5.6.3.2. Mexico Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 5.6.3.2.1. Prescription Drugs 5.6.3.2.2. OTC Drugs 5.6.3.3. Mexico Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 5.6.3.3.1. Peripherally Acting Anti-Obesity Drugs 5.6.3.3.2. Centrally Acting Anti-obesity Drugs 5.6.3.4. Mexico Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 5.6.3.4.1. Direct Channel 5.6.3.4.2. Distribution Channel 5.6.3.5. Mexico Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 5.6.3.5.1. Hospitals Pharmacies 5.6.3.5.2. Retail Pharmacies 5.6.3.5.3. E-commerce 6. Europe Anti-Obesity Prescription Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 6.1. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.2. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.3. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.4. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.5. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Country (2024-2032) 6.6.1. United Kingdom 6.6.1.1. United Kingdom Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.1.2. United Kingdom Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.1.3. United Kingdom Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.1.4. United Kingdom Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.1.5. United Kingdom Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6.2. France 6.6.2.1. France Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.2.2. France Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.2.3. France Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.2.4. France Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.2.5. France Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6.3. Germany 6.6.3.1. Germany Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.3.2. Germany Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.3.3. Germany Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.3.4. Germany Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.3.5. Germany Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6.4. Italy 6.6.4.1. Italy Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.4.2. Italy Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.4.3. Italy Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.4.4. Italy Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.4.5. Italy Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6.5. Spain 6.6.5.1. Spain Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.5.2. Spain Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.5.3. Spain Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.5.4. Spain Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.5.5. Spain Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6.6. Sweden 6.6.6.1. Sweden Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.6.2. Sweden Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.6.3. Sweden Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.6.4. Sweden Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.6.5. Sweden Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6.7. Austria 6.6.7.1. Austria Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.7.2. Austria Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.7.3. Austria Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.7.4. Austria Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.7.5. Austria Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 6.6.8. Rest of Europe 6.6.8.1. Rest of Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 6.6.8.2. Rest of Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 6.6.8.3. Rest of Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 6.6.8.4. Rest of Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 6.6.8.5. Rest of Europe Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7. Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 7.1. Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.2. Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.3. Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.4. Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.5. Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6. Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Country (2024-2032) 7.6.1. China 7.6.1.1. China Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.1.2. China Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.1.3. China Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.1.4. China Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.1.5. China Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.2. S Korea 7.6.2.1. S Korea Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.2.2. S Korea Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.2.3. S Korea Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.2.4. S Korea Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.2.5. S Korea Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.3. Japan 7.6.3.1. Japan Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.3.2. Japan Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.3.3. Japan Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.3.4. Japan Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.3.5. Japan Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.4. India 7.6.4.1. India Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.4.2. India Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.4.3. India Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.4.4. India Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.4.5. India Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.5. Australia 7.6.5.1. Australia Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.5.2. Australia Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.5.3. Australia Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.5.4. Australia Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.5.5. Australia Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.6. Indonesia 7.6.6.1. Indonesia Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.6.2. Indonesia Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.6.3. Indonesia Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.6.4. Indonesia Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.6.5. Indonesia Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.7. Malaysia 7.6.7.1. Malaysia Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.7.2. Malaysia Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.7.3. Malaysia Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.7.4. Malaysia Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.7.5. Malaysia Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.8. Vietnam 7.6.8.1. Vietnam Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.8.2. Vietnam Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.8.3. Vietnam Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.8.4. Vietnam Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.8.5. Vietnam Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.9. Taiwan 7.6.9.1. Taiwan Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.9.2. Taiwan Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.9.3. Taiwan Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.9.4. Taiwan Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.9.5. Taiwan Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 7.6.10. Rest of Asia Pacific 7.6.10.1. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 7.6.10.2. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 7.6.10.3. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 7.6.10.4. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 7.6.10.5. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 8. Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 8.1. Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 8.2. Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 8.3. Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 8.4. Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 8.5. Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 8.6. Middle East and Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Country (2024-2032) 8.6.1. South Africa 8.6.1.1. South Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 8.6.1.2. South Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 8.6.1.3. South Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 8.6.1.4. South Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 8.6.1.5. South Africa Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 8.6.2. GCC 8.6.2.1. GCC Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 8.6.2.2. GCC Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 8.6.2.3. GCC Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 8.6.2.4. GCC Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 8.6.2.5. GCC Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 8.6.3. Nigeria 8.6.3.1. Nigeria Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 8.6.3.2. Nigeria Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 8.6.3.3. Nigeria Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 8.6.3.4. Nigeria Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 8.6.3.5. Nigeria Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 8.6.4. Rest of ME&A 8.6.4.1. Rest of ME&A Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 8.6.4.2. Rest of ME&A Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 8.6.4.3. Rest of ME&A Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 8.6.4.4. Rest of ME&A Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 8.6.4.5. Rest of ME&A Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 9. South America Anti-Obesity Prescription Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2024-2032 9.1. South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 9.2. South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 9.3. South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class(2024-2032) 9.4. South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 9.5. South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 9.6. South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Country (2024-2032) 9.6.1. Brazil 9.6.1.1. Brazil Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 9.6.1.2. Brazil Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 9.6.1.3. Brazil Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 9.6.1.4. Brazil Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 9.6.1.5. Brazil Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 9.6.2. Argentina 9.6.2.1. Argentina Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 9.6.2.2. Argentina Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 9.6.2.3. Argentina Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 9.6.2.4. Argentina Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 9.6.2.5. Argentina Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 9.6.3. Rest Of South America 9.6.3.1. Rest Of South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Type (2024-2032) 9.6.3.2. Rest Of South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Type (2024-2032) 9.6.3.3. Rest Of South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Drug Class (2024-2032) 9.6.3.4. Rest Of South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Sales Channel (2024-2032) 9.6.3.5. Rest Of South America Anti-Obesity Prescription Drugs Market Size and Forecast, by Application (2024-2032) 10. Company Profile: Key Players 10.1. F Hoffmann La Roche 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Arena Pharmaceuticals 10.3. Orexigen Therapeutics 10.4. Phentermine and Topiramate 10.5. VIVUS, Inc 10.6. Liraglutide 10.7. Bupropion and Naltrexone 10.8. Orlistat 10.9. Novo Nordisk 10.10. Lorcaserin 10.11. GlaxoSmith Kline 10.12. Eisai Co, Ltd 10.13. Boehringer Ingelheim 10.14. Merck & Co 10.15. Pfizer 10.16. Rhythm Pharmaceuticals 10.17. Zafgan 10.18. Takeda Pharmaceuticals 10.19. Novo Nordisk 10.20. Bristol-Myers Squibb Co. 10.21. Shionogi USA Inc 10.22. Norgine by 11. Key Findings 12. Industry Recommendations 13. Anti-Obesity Prescription Drugs Market: Research Methodology 14. Terms and Glossary
